R97.21 – Rising PSA following treatment for malignant neoplasm of prostate
ICD-10-CM 2027 diagnosis code · Abnormal tumor markers (R97)
ICD-10-CM code
R97.21
- Code
R97.21(claims format:R9721)- Description
- Rising PSA following treatment for malignant neoplasm of prostate
- Short description
- Rising PSA fol treatment for malignant neoplasm of prostate
- Billable
- Yes – valid for HIPAA-covered transactions
- Valid for
- Dates of service October 1, 2026 – September 30, 2027 (FY2027)
- Chapter
- 18. Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R99)
- Block
- R97 Abnormal tumor markers (R97)
- Parent codes
- R97 › R97.2
Notes inherited from parent codes
Instructional notes at a category or block level apply to every code below it.
R97 – Abnormal tumor markers
Applicable to:
- Elevated tumor associated antigens [TAA]
- Elevated tumor specific antigens [TSA]
Index terms for R97.21
Entries in the ICD-10-CM alphabetic index that lead to this code:
Related codes in R97.2
Frequently asked questions
What is ICD-10 code R97.21?
R97.21 is the ICD-10-CM code for rising PSA following treatment for malignant neoplasm of prostate, in the block R97 (Abnormal tumor markers (R97)).
Is R97.21 a billable code?
Yes. R97.21 is a billable/specific code that can be used to indicate a diagnosis for reimbursement purposes.
What category does R97.21 belong to?
It belongs to category R97 – Abnormal tumor markers.
Source: CDC/NCHS ICD-10-CM FY2027 code files, tabular list and index. Reference only – code assignment must follow the official ICD-10-CM guidelines and documentation in the medical record.